Mersana Therapeutics Inc MRSN:NASDAQ

Last Price$3.49NASDAQ Closing Price as of 4:00PM ET 5/20/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change+0.04(1.16%)
Bid (Size)$3.49 (259)
Ask (Size)$3.50 (4)
Day Low / High$3.37 - 3.63
Volume1.5 M
 

View Biotechnology IndustryPeer Comparison as of 05/20/2022

 

Mersana Therapeutics Inc ( NASDAQ )

Price: $3.49
Change: +0.04 (1.16%)
Volume: 1.5 M
4:00PM ET 5/20/2022
 
 

Kezar Life Sciences Inc ( NASDAQ )

Price: $5.54
Change: +0.05 (0.91%)
Volume: 3.6 M
4:00PM ET 5/20/2022
 
 

Outlook Therapeutics Inc ( NASDAQ )

Price: $1.57
Change: +0.05 (3.29%)
Volume: 621.8 K
4:00PM ET 5/20/2022
 
 

Kodiak Sciences Inc ( NASDAQ )

Price: $6.96
Change: +0.25 (3.73%)
Volume: 950.6 K
4:00PM ET 5/20/2022
 
 

Enochian Biosciences Inc ( NASDAQ )

Price: $6.26
Change: +0.23 (3.81%)
Volume: 146.7 K
4:00PM ET 5/20/2022
 

Read more news Recent News

Sector Update: Health Care Stocks Fall Pre-Bell Thursday
9:19AM ET 5/19/2022 MT Newswires

Health care stocks fell pre-bell Thursday. The Health Care SPDR (XLV) was 0.66% lower and the iShares NASDAQ Biotechnology Index (IBB) was down 0.54%. SIGA...

Mersana Therapeutics Says FDA has Granted XMT-2056 Orphan Drug Status to Treat Gastric Cancer; Shares Surge Pre-Bell
7:38AM ET 5/19/2022 MT Newswires

Mersana Therapeutics (MRSN) said Thursday the US Food and Drug Administration has granted Orphan Drug designation to XMT-2056 to treat gastric cancer. The...

--Baird Adjusts Mersana Therapeutics' Price Target to $18 From $23, Keeps Outperform Rating
9:16AM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Mersana Therapeutics Price Target to $14 From $18, Maintains Outperform Rating
1:08PM ET 5/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionMersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA. View company web site for more details
Address840 Memorial Drive
Cambridge, Massachusetts 02139
Phone+1.617.498.0020
Number of Employees86
Recent SEC Filing05/18/20224
President, Chief Executive Officer & DirectorAnna Protopapas
Chief Financial Officer & Senior Vice PresidentBrian DeSchuytner
Chief Science & Technology OfficerTimothy B. Lowinger
Chief Medical Officer & Senior Vice PresidentArvin Yang

Company Highlights

Price Open$3.51
Previous Close$3.45
52 Week Range$2.68 - 15.34
Market Capitalization$338.5 M
Shares Outstanding97.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/05/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.49
Beta vs. S&P 500N/A
Revenue$10.6 M
Net Profit Margin-8,826.73%
Return on Equity-119.10%

Analyst Ratings as of 03/18/2022

Buy
5
Overweight
1
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset